Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group's TQB2102 was granted breakthrough therapy designation by China's National Medical Products Administration.
The drug is for adult patients with unresectable or metastatic HER2-low breast cancer.
This is the third breakthrough therapy designation granted to the drug.